secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2024-07-03T23:59:59+00:00
Accession:  0001551152-24-000024
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie lowers 2024 adjusted EPS guidance to $10.61-$10.81 on $937M IPR&D charge
-------------------------------------------------------------------------------

- Preliminary Q2 2024 acquired IPR&D and milestones expense of $937 million pre-tax.
- GAAP and adjusted non-GAAP diluted EPS each reduced by $0.52 in Q2.
- Q2 2024 adjusted diluted EPS guidance set at $2.53-$2.57.
- Full-year 2024 adjusted diluted EPS guidance lowered to $10.61-$10.81 from $11.13-$11.33.
- Guidance excludes any future IPR&D expense beyond Q2; final Q2 results subject to closing procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000024/0001551152-24-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000024/abbv-20240703.htm
  HTML page:      https://secwatch.observer/filing/0001551152-24-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer